Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Rosa & Co. LLC
SAN CARLOS, Calif., Feb. 11, 2014 /PRNewswire/ -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation research, today announced that Dr. Ron D. Beaver, Ph.D., CEO will present a webinar entitled "Systems Pharmacology: Science or Non-Science? And so what?" in Rosa's "Impact of Modeling & Simulation in Drug Development" Webinar series on February 27th, 2014 at 1:00 pm EST (GMT -5:00).
The biopharmaceutical industry has slowly adopted drug-disease modeling and simulation (M&S) over the past two decades; nevertheless, as a whole, the industry continues to view M&S as an optional activity, peripheral to the mainstream scientific activity of drug development. This view is largely due to the implicit belief that M&S is something other than science. This webinar will explore the question of whether quantitative systems pharmacology, a powerful M&S approach, is, in fact, "scientific," and the implications of the answer for scientific progress, organizational design, and M&S adoption. To illustrate the concepts, two diverse applications of systems pharmacology will be presented.
The purpose of the series, "Impact of Modeling & Simulation in Drug Development," is to foster the use of M&S activities in biotechnology, pharmaceutics, and other life science industries. This series is geared to illustrate the advantages and applicability of M&S in product discovery, development, and marketing programs.
Register for this free Webinar. After registering, you will receive a confirmation email containing information about how to join the webinar. More information about the Webinar series may be found at http://www.rosaandco.com/webinar.html.
Rosa helps clients better understand complex biology and inform their critical decisions – from preclinical through clinical development – with the creation and use of flexible mathematical models that simulate normal and disease physiology, drug action, patient variability, and trial outcomes. Rosa offers both PhysioPD™ Research Platforms and classic PK/PD models. Rosa's clients participate in customized model development and testing processes, retain the resulting models, and acquire the ability to perform simulation research to improve their understanding of the implications for their pharmaceutical, consumer, and veterinary product development programs. Rosa has unparalleled experience in applying modeling and simulation to expand our understanding of biology and accelerate product development. The Rosa team is unique in its breadth and depth of disease area experience, including metabolic, cardiovascular, oncology, inflammation, immune dysfunction, CNS, respiratory, dermatology, nutrition, and antibacterial/antiviral biology. For more information, visit www.rosaandco.com.
Read more news from Rosa and Co.
©2012 PR Newswire. All Rights Reserved.